Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report

Crizotinib, an oral ATP-competitive tyrosine kinase inhibitor (TKI), has shown significant activity against advanced non-small cell lung cancer (NSCLC) tumors harboring mesenchymal-epithelial transition (MET) amplification or exon 14 mutation. Methods to detect MET alteration includes immunohistoche...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Peng, Liu, Li, Liu, Yutao, Zhang, Tao, Guo, Lei, Li, Weihua, Ying, Jianming, Yang, Lin, Gao, Shugeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798553/
https://www.ncbi.nlm.nih.gov/pubmed/35116804
http://dx.doi.org/10.21037/tcr.2019.03.14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798553/
https://www.ncbi.nlm.nih.gov/pubmed/35116804
http://dx.doi.org/10.21037/tcr.2019.03.14

Ejemplares similares